Calls
1
u/Thescorerocket
Reddit r/pennystocks
Win Rate
0.0%
return
-62.3%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 04
$9.71
-62.3%
Lexaria's DehydraTECH Phase 1b data showed fewer GI side effects than Rybelsus while achieving metabolic parity and less lean-mass loss, moving the technology into a clinically relevant signal. The same study demonstrated oral feasibility with tirzepatide, suggesting DehydraTECH is a platform while Novo Nordisk's SNAC oral franchise has IP/strategic constraints and Lilly needs oral delivery without adherence issues. With Phase 1b risk retired and funding secured into 2026, Lexaria's delivery technology has become a strategic negotiating lever in the oral GLP-1 race.
Other
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Thescorerocket has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: LEXX.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
